Status:
COMPLETED
Improving Followup of Abnormal Colon Cancer Screening Tests
Lead Sponsor:
Harvard Vanguard Medical Associates
Collaborating Sponsors:
Brigham and Women's Hospital
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether direct mailings to patients with positive fecal occult blood tests can increase rates of performing followup colonoscopy.
Detailed Description
Screening programs using the fecal occult blood test (FOBT) have demonstrated a significant reduction in colorectal cancer mortality, although only when accompanied by a complete diagnostic evaluation...
Eligibility Criteria
Inclusion
- Patients with positive fecal occult blood test during 2004, 2005, and 2006; and no colonoscopy following this test result
Exclusion
- Patients with active cardiopulmonary disease or limited life expectancy due to severe illness such as malignancy
- Colonoscopy within 5 years prior to positive fecal occult blood test
- Age \> 80 years
Key Trial Info
Start Date :
June 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00436137
Start Date
June 1 2007
End Date
March 1 2008
Last Update
November 6 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Harvard Vanguard Medical Associates
Newton, Massachusetts, United States, 02466